Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript

SA Transcripts159.1K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Transgene SA (TRGNF) Q4 2025 Earnings Call March 24, 2026 1:00 PM EDT Company Participants Lucie Larguier - VP & Chief Financial OfficerAlessandro Riva - CEO & Chairman of the Board Conference Call Participants Chiara Montironi - Kempen & Co. N.V., Research DivisionDominic Rose - Intron Health Advisors Ltd Presentation Operator Good day, and thank you for standing by. Welcome to the Transgene 2025 Annual Results and Prospective for 2026 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Lucie Larguier. Please go ahead. Lucie LarguierVP & Chief Financial Officer Well, thank you, Nadia, and hello, everyone. So I'm Lucie, Chief Financial Officer at Transgene, and I'm with Dr. Alessandro Riva, our Chairman and CEO today. We will review the progress over 2025 and answer any questions you may have. Before I turn the call over to Alessandro, I'd like to remind everyone that today's discussion contains forward-looking statements which are subject to multiple risks and uncertainties. [Operator Instructions] With this, I now turn the call over to Alessandro. Alessandro RivaCEO & Chairman of the Board Thanks, Lucie, and good morning, good evening, good afternoon, everyone. So 2025 has been a year of meaningful clinical progress for Transgene. As you all know, we advanced our individualized neoantigen therapeutic vaccine, INTV, TG4050, supported by compelling clinical and translational data in head and neck cancer that reinforce our confidence in its potential to prevent relapse in patients. I would say that there were 3 crucial moments this year that confirm our conviction that the myvac platform can bring benefit to patients. First of all, our Phase I data being presented already at ASCO in the same section as 2 Phase